Ten-year screening for thrombocytopenia after aortic valve replacement

Area of Science:

• Cardiovascular Surgery
• Hematology
• Immunology

Background:

• Thrombocytopenia is a frequent complication following cardiac surgery.
• Diagnosing heparin-induced thrombocytopenia is challenging due to limitations in current laboratory tests.
• The effectiveness of screening programs for managing postoperative thrombocytopenia remains unclear.

Purpose of the Study:

• To evaluate the success of a local screening program for postoperative thrombocytopenia.
• To determine the incidence and predictors of thrombocytopenia after aortic valve replacement (AVR).
• To assess the association between thrombocytopenia, anti-platelet factor 4/heparin antibody (Elisa) status, and clinical outcomes.

Main Methods:

• A screening protocol was implemented for cardiac surgery patients starting in 2002.
• Patients were tested postoperatively for thrombocytopenia and stratified using the anti-platelet factor 4/heparin antibody (Elisa) test.
• Clinical data, including preoperative and operative characteristics and outcomes, were collected from a departmental registry.

Main Results:

• A total of 16,529 patients were screened; 1,261 undergoing isolated AVR were analyzed.
• The incidence of thrombocytopenia post-AVR was 26.8%, with Elisa positivity in 3.4% of patients.
• Elisa positivity was associated with increased operative mortality, stroke, bleeding, and a higher likelihood of receiving bioprosthetic valves.

Conclusions:

• Thrombocytopenia and Elisa positivity are more prevalent after AVR compared to other cardiac procedures.
• Both thrombocytopenia and Elisa positivity are linked to adverse clinical outcomes post-AVR.
• Advanced age and lower preoperative platelet counts are independent predictors of postoperative thrombocytopenia and Elisa positivity.